Opportunities for quantitative translational modelling in oncology

Author: 

Yates, J
Byrne, H
Chapman, S
Chen, T
Cucurull-Sanchez, L
Delgado-SanMartin, J
di Veroli, G
Dovedi, S
Dunlop, C
Jena, R
Jodrell, D
Martin, E
Mercier, F
Ramos-Montoya, A
Struemper, H
Vicini, P

Publication Date: 

25 July 2020

Journal: 

Clinical Pharmacology and Therapeutics

Last Updated: 

2020-11-08T13:46:42.617+00:00

DOI: 

10.1002/cpt.1963

abstract: 

<p>A 2‐day meeting was held by members of the UK Quantitative Systems Pharmacology Network (<http://www.qsp‐uk.net/>) in November 2018 on the topic of Translational Challenges in Oncology. Participants from a wide range of backgrounds were invited to discuss current and emerging modeling applications in nonclinical and clinical drug development, and to identify areas for improvement. This resulting perspective explores opportunities for impactful quantitative pharmacology approaches. Four key themes arose from the presentations and discussions that were held, leading to the following recommendations:</p><br>

‐Evaluate the predictivity and reproducibility of animal cancer models through precompetitive collaboration.<br>
‐Apply mechanism of action (MoA) based mechanistic models derived from nonclinical data to clinical trial data.<br>
‐Apply MoA reflective models across trial data sets to more robustly quantify the natural history of disease and response to differing interventions.<br>
‐Quantify more robustly the dose and concentration dependence of adverse events through mathematical modelling techniques and modified trial design.<br>

Symplectic id: 

1109593

Submitted to ORA: 

Submitted

Publication Type: 

Journal Article